NYMC Faculty Publications

Title

Myasthenic Crisis in the Setting of Coronavirus Disease 2019 (COVID-19)

First Page

110001

Last Page

110001

Document Type

Case Report

Publication Date

12-1-2020

Department

Anesthesiology

Abstract

  1. A patient with Myasthenia Gravis (MG) on immunosuppressive therapy with underlying respiratory compromise may be more susceptible to infection with COVID-19 or severe manifestations of the virus.

  2. It is theorized that patients with MG may be more vulnerable to bacterial and viral infections, due to respiratory muscle weakness and use of immunosuppressive medications.

  3. It is critical for practitioners to be prepared for severe respiratory compromise in patients with MG and concomitant COVID-19 superinfection.

  4. In light of the COVID-19 pandemic, MG patients should be encouraged to continue their current treatment regimens, but engage in extra vigilant social distancing.

This document is currently not available here.

Share

COinS